A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Technologies announced positive topline results from its Phase 2 study of PL8177, a selective melanocortin-1 receptor agonist, in ...

(RTTNews) - Palatin Technologies, Inc. (PTN) Friday reported positive topline results from its Phase 2 study of PL8177 in patients with active ulcerative colitis (UC), a form of inflammatory bowel ...

The study, focusing on safety, tolerability, and efficacy, showed that 33% of patients treated with PL8177 achieved clinical remission compared to none on placebo after eight weeks. According to ...

Topline results from our Phase 2 clinical study of PL8177 oral formulation for the treatment of UC expected later this quarter. Diabetic nephropathy Phase 2B study in patients with Type 2 diabetic ...

A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin Technologies’ melanocortin-1 receptor (MC1R) agonist, PL8177. The company ...

CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $18.2 million, has announced encouraging results from its Phase 2 trial of ...

Phase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarter Teleconference and Webcast to be held on February 13 ...

Topline results from our Phase 2 clinical study of PL8177 oral formulation for the treatment of UC expected later this quarter. Diabetic nephropathy Phase 2B study in patients with Type 2 diabetic ...